Advancing the global public health agenda for NAFLD: a consensus statement
Продвижение глобальной повестки общественного здравоохранения в отношении НАЖБП: консенсусное заявление
2021-10-27
SCID: 54.1/8sn47yh3
Discuss with AI
Delphi studyglobal public healthmetabolic syndromenon-alcoholic fatty liver diseasenon-communicable diseases
Figures from the paper
Abstract (AI)
Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics — from epidemiology, awareness, care and treatment to public health policies and leadership — that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD. Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease with a substantial burden worldwide. In this Consensus Statement, a global multidisciplinary group of experts develop consensus statements and recommendations addressing a broad range of topics on NAFLD to raise awareness and spur action.
Key Findings
1
A global multidisciplinary Delphi process produced consensus statements and recommendations spanning epidemiology, awareness, care, treatment, public health policy, and leadership.
2
Global public health and health-system responses to NAFLD are weak and fragmented, with the disease largely absent from national and international non-communicable disease strategies.
3
NAFLD affects approximately one-quarter of the global adult population and creates substantial health, social, and economic burdens.
4
NAFLD is a multisystem disease and the hepatic component of metabolic syndrome, yet it remains largely unrecognized outside hepatology and gastroenterology.
5
The recommendations provide a foundation for comprehensive public health action involving policymakers, healthcare practitioners, civil society, researchers, and affected populations.
Research Object
non-alcoholic fatty liver disease (NAFLD) and the global public health response to it
Research Subject
the epidemiology, awareness, care and treatment, public health policies, and leadership needed to advance NAFLD prevention and management
Publication Details
Publication Date
2021-10-27
Journal
Publisher
ISSN
Cited by
783
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 20192020
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases2017
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 20152016
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 20172019